Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 4/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL636159 | 0.94 | APLNR (0.38) | HCRTR1HCRTR2MAPTTP53PKM | |
| SCHEMBL636196 | 0.94 | APLNR (0.35) | HCRTR1HCRTR2MAPTTP53PKM | |
| SCHEMBL636548 | 0.93 | MAPT (0.35) | HCRTR1HCRTR2MAPTTP53PKM | |
| SCHEMBL638077 | 0.93 | ACMSD (0.33) | HCRTR1HCRTR2MAPTTP53PKM | |
| SCHEMBL637598 | 0.93 | APLNR (0.37) | MAPTTP53PKML3MBTL1ALDH1A1 | |
| SCHEMBL638081 | 0.93 | MAPT (0.33) | HCRTR1HCRTR2MAPTTP53PKM | |
| SCHEMBL636240 | 0.92 | GPR139 (0.33) | MAPTTP53PKML3MBTL1ALDH1A1 | |
| SCHEMBL4401369 | 0.92 | GPR139 (0.33) | MAPTTP53PKML3MBTL1ALDH1A1 | |
| SCHEMBL636525 | 0.91 | KCNQ3 (0.33) | HCRTR1HCRTR2MAPTTP53PKM | |
| SCHEMBL16966532 | 0.91 | NFE2L2 (0.40) | MAPTTP53PKML3MBTL1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2283017-B1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2015-08-05 | — | — | EP | claimed |
| US-8518955-B2 | Fused pyrimidineone compounds as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-27 | — | — | US | claimed |
| US-20120115886-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. | 2012-05-10 | — | — | US | claimed |
| US-8119647-B2 | Fused pyrimidineone compounds as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-21 | — | — | US | claimed |
| US-20090286811-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. | 2009-11-19 | — | — | US | claimed |
| EP-2283017-B1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-8518955-B2 | Fused pyrimidineone compounds as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-27 | — | — | US | disclosed |
| EP-2626360-A1 | Process for the preparation of fused pyrimidineone compounds useful as TRPV3 modulators | Glenmark Pharmaceuticals S.A. (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-20120115886-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. | 2012-05-10 | — | — | US | disclosed |
| US-20120108813-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. | 2012-05-03 | — | — | US | disclosed |
| US-8119647-B2 | Fused pyrimidineone compounds as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20090286811-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286811-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV4 | HCRTR1 1984/4885HCRTR2 1487/4885MAPT 2368/4885 |
| US-20120115886-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV4 | HCRTR1 1984/4885HCRTR2 1487/4885MAPT 2368/4885 |
| US-20120108813-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV4 | HCRTR1 1984/4885HCRTR2 1487/4885MAPT 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.